Skip to main
TNYA
TNYA logo

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc has demonstrated encouraging early results in its Phase 1b study of TN-201, showing increases in protein levels and positive trends in clinical parameters related to heart disease. The company's focus on gene therapy, cellular regeneration, and precision medicine positions it well within the biotechnology sector, particularly as gene therapies are increasingly recognized for their potential as one-time treatments with lasting effects. Financial results for the fourth quarter of 2024 and the full year were in line with analyst estimates, indicating a stable financial outlook as the company advances its innovative therapies to address significant unmet medical needs in heart disease.

Bears say

Tenaya Therapeutics Inc faces significant risks that could lead to a negative impact on its stock, particularly due to potential delays in transitioning its preclinical assets to clinical trials and the emergence of critical safety signals, which may adversely affect market sentiment and revenue forecasts. The complexity and novelty of the company's AAV-based gene therapy products heighten the risk of manufacturing challenges, which could further delay product development and commercialization despite ongoing investments in internal capabilities. Additionally, the company may face financial constraints from unsuccessful clinical trials or the need for dilutive capital raises, which could hinder its ability to secure funding necessary to advance its drug development efforts.

Tenaya Therapeutic (TNYA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Buy based on their latest research and market trends.

According to 6 analysts, Tenaya Therapeutic (TNYA) has a Buy consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.